“We have been working towards a multi-indication PBS listing for nivolumab and ipilimumab with the PBAC since 2017. We have maintained momentum throughout this period as we have always understood the importance and impact of expedited access for Australian patients,” said Owen Smith, General Manager of Bristol Myers Squibb Australia and New Zealand. …
PBS listing expands access to immunotherapy for Australians with advanced cancer
March 1, 2026 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Just in case they didn't get the message, Mark Butler has reminded them of the Government's view
July 7, 2026 - - Latest News -
Australian Healthcare Associates retains deal to administer the CSO funding pool through 2029
July 7, 2026 - - Latest News -
Just another attempt to create a new excuse to avoid a meaningful discussion about change
July 7, 2026 - - Latest News -
Australia must keep development manufacturing and jobs here to secure health and economic benefits
July 7, 2026 - - Latest News -
Brandon Capital secures landmark Novartis acquisition of Myricx Bio
July 6, 2026 - - Latest News -
Vitex opens $250 million pharmaceutical manufacturing facility in Western Sydney
July 6, 2026 - - Latest News -
Early clinical imaging shows Syntara candidate reduces brain inflammation in people at high risk of Parkinson’s
July 6, 2026 - - Australian Biotech